文献速递浆细胞疾病

骨髓免疫生态系统塑造浆细胞骨髓瘤中达雷妥尤单抗获得性耐药

The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma.
PubMed 文献 · Leukemia · 2025-08-01

该研究比较浆细胞骨髓瘤患者达雷妥尤单抗治疗前与获得性耐药后的配对样本,采用单细胞RNA测序和数字空间分析。耐药后细胞毒性CD8阳性T细胞耗竭表型及IFN-γ特征比例增加,NK细胞比例减少且抑制性表型增加,肿瘤浆细胞CD38转录下降。骨髓免疫生态系统分泌的IFN-γ激活MYC,与获得性耐药相关。

要点

  • 耐药后细胞毒性CD8阳性T细胞耗竭表型和IFN-γ特征比例增加,NK细胞比例减少且抑制性表型增加。
  • 肿瘤浆细胞CD38转录下降,DSP定义的癌症中心免疫细胞数量显著减少伴耗竭特征增加。
  • 获得性耐药特征和高浆细胞瘤亚群表型与4个外部队列中更差预后相关。

核心结论

  • 骨髓免疫生态系统分泌的IFN-γ激活MYC,与浆细胞骨髓瘤达雷妥尤单抗获得性耐药相关。

研究设计与样本

  • 比较浆细胞骨髓瘤受试者达雷妥尤单抗治疗前与获得性耐药后的配对样本,采用单细胞RNA测序和数字空间分析(DSP)。

主要发现

  • 耐药样本较治疗前样本,耗竭表型细胞毒性CD8阳性T细胞比例增加且IFN-γ特征增加,NK细胞比例减少且抑制性表型增加。
  • 肿瘤浆细胞CD38转录下降,DSP定义的癌症中心免疫细胞数量显著减少伴耗竭特征增加。
  • 获得性耐药特征和高浆细胞瘤亚群表型与4个外部队列(GSE24080、GSE136337、GSE57317和coMMpass)中更差预后相关。
  • 单细胞调控网络推断显示,MYC调控是获得性耐药肿瘤浆细胞的关键激活因子。
  • 体外和体内实验数据表明,骨髓免疫生态系统细胞分泌的IFN-γ激活MYC,与获得性达雷妥尤单抗耐药相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Daratumumab, an anti-CD38 monoclonal antibody, is an effective therapy for plasma cell myeloma (PCM). However, many initial responders relapse. We compared paired samples from subjects pre-therapy and then acquired resistance to daratumumab. We first used single-cell RNA sequencing and digital spatial profiler (DSP). The proportion of cytotoxic CD8-positive T-cells with an exhaustion phenotype and an IFN-γ signature increased in resistance compared with pre-therapy samples, whilst the proportion of NK-cells decreased and had an increased inhibitory phenotype. Transcription of CD38 in neoplastic plasma cells decreased. Numbers of immune cells in cancer centre defined by DSP were significantly decreased in parallel with an increased exhaustion signature. The acquired resistance signature and elevated PCM subset phenotype were associated with worse prognosis in 4 external cohorts (GSE24080, GSE136337, GSE57317, and coMMpass). Using single-cell regulatory network inference, we identified MYC regulation as a key activated factor for acquired resistance in neoplastic plasma cells by intersecting the top 20 upregulated regulons and upregulated genes in acquired resistance. Furthermore, data from in vitro and in vivo experiments indicate that IFN-γ secreted by cells of bone marrow immune ecosystem activates MYC, which correlates with acquired daratumumab resistance. Our data provide insights into acquired daratumumab resistance and suggest potential therapeutic strategies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wang Y, Chen S, Liang Z, et al. The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma. Leukemia. 2025. PMID: 40750676. doi:10.1038/s41375-025-02712-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。